Pharmaceutical - Markets & Marketing, Bayer

Filter

Current filters:

Markets & MarketingBayer

Popular Filters

1 to 25 of 59 results

Bayer’s Jadelle to be listed in New Zealand

Bayer’s Jadelle to be listed in New Zealand

26-09-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

BayerJadelleMarkets & MarketingNew ZealandPharmaceuticalPricingReproductiveWomen's Health

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

11-08-2014

The treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through…

BayerGleevecGlivecMarkets & MarketingNovartisOncologyPfizerPharmaceuticalStivargaSutent

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Bayer’s Diane-35 back on French market

Bayer’s Diane-35 back on French market

16-01-2014

Following the confirmation of the positive benefit-risk profile by the European Medicines Agency, German…

BayerDermatologicalsDiane-35EuropeFranceMarkets & MarketingPharmaceutical

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

What does the future hold for pharma?

What does the future hold for pharma?

22-11-2013

Here's our take on the week's top stories.

AstraZenecaBayerBiotechnologyCerulean PharmaMarkets & MarketingPharmaceuticalResearchSanofi

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019

13-11-2013

The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Bayer joins string of drugmakers being investigated in China

16-09-2013

German pharma and crop sciences major Bayer (BAYN: DE) is being investigated in China over a "potential…

Asia-PacificBayerLegalMarkets & MarketingPharmaceutical

Bayer links with DKSH to expand in Singapore

10-09-2013

DKSH Business Unit Healthcare, a leading partner for health care companies seeking to grow their business…

Asia-PacificBayerMarkets & MarketingPharmaceutical

Germany's Bayer plans to boost sales in Russia by 80% by 2017

06-09-2013

German pharmaceutical, material and crop sciences major Bayer's (BAYN: DE) chief executive Marijn Dekkers…

BayerFinancialMarkets & MarketingPharmaceutical

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

New entrants to multiple sclerosis market will drive 10% pa growth through 2018

26-07-2013

The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

1 to 25 of 59 results

Back to top